Pharming Group N.V. provided earnings guidance for the remainder of 2021. For the period, the company expected continued growth in revenues from sales of RUCONEST®, mainly driven by the US and expanded EU operations, subject to the progression of the COVID-19 pandemic, with quarterly fluctuations in revenues expected, as a result of the ongoing effects of the pandemic on access to customers and phasing of ordering patterns. Maintenance of positive net earnings during the year, therefore do not expect to require additional financing to maintain the current business.